Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04874558 · ClinicalTrials.gov registry record
Ultra-low-dose Chest CT for HHT
A clinical trial of Hereditary Hemorrhagic Telangiectasia, sponsored by Mayo Clinic.
- Active
- Registry status
- 10
- Enrollment target
- 1
- Study location
NCT04874558 is a study of Hereditary Hemorrhagic Telangiectasia that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 10 participants, below the 1,789-participant average among 7 other Hereditary Hemorrhagic Telangiectasia trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04874558, a study of Hereditary Hemorrhagic Telangiectasia, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to develop a novel ultra-low dose chest CT technology for use in Hereditary Hemorrhagic Teleangiectasia (HHT) patients and to determine the lowest possible radiation dose that is achievable without sacrificing the diagnostic quality.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Ultra-low dose chest CT
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-04-21 |
| Est. Completion | 2025-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04874558
The ClinicalTrials.gov registry entry for NCT04874558 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,789-participant average among 7 other Hereditary Hemorrhagic Telangiectasia trials with a reported enrollment target (99% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hereditary Hemorrhagic Telangiectasia appearing as the primary indexed condition, and to 1 intervention - of which Ultra-low dose chest CT is the first listed.
NCT04874558 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT04874558 about?
NCT04874558 is a clinical study titled "Ultra-low-dose Chest CT for HHT". This study aims to develop a novel ultra-low dose chest CT technology for use in Hereditary Hemorrhagic Teleangiectasia (HHT) patients and to determine the lowest possible radiation dose that is achievable without sacrificing the diagnostic quality.
What is the current status of trial NCT04874558?
This trial is currently active not recruiting. The enrollment target is 10 participants. The study started on 2021-04-21. Estimated completion is 2025-12-31.
What conditions does trial NCT04874558 study?
This clinical trial studies the following conditions: Hereditary Hemorrhagic Telangiectasia.
What interventions are being tested in trial NCT04874558?
The interventions under investigation include: Ultra-low dose chest CT (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04874558?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04874558 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Hemorrhagic Telangiectasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comprehensive HHT Outcomes Registry of the United States (CHORUS)
RECRUITING
-
A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
RECRUITING · Phase 1
-
Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia
ACTIVE NOT RECRUITING
-
Bevacizumab In Hereditary Hemorrhagic Telangiectasia
ACTIVE NOT RECRUITING · Phase 2
-
Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)
ACTIVE NOT RECRUITING · Phase 2
-
Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.